Works matching IS 00070920 AND DT 2012 AND VI 107 AND IP 8

Results: 37
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.

    Published in:
    British Journal of Cancer, 2012, v. 107, n. 8, p. 1423, doi. 10.1038/bjc.2012.380
    By:
    • Hatzimichael, E;
    • Lo Nigro, C;
    • Lattanzio, L;
    • Syed, N;
    • Shah, R;
    • Dasoula, A;
    • Janczar, K;
    • Vivenza, D;
    • Monteverde, M;
    • Merlano, M;
    • Papoudou-Bai, A;
    • Bai, M;
    • Schmid, P;
    • Stebbing, J;
    • Bower, M;
    • Dyer, M J S;
    • Karran, L E;
    • ElguetaKarstegl, C;
    • Farrell, P J;
    • Thompson, A
    Publication type:
    Article
    12
    13
    14
    15
    16
    17

    Quality of life in participants of a CRC screening program.

    Published in:
    British Journal of Cancer, 2012, v. 107, n. 8, p. 1295, doi. 10.1038/bjc.2012.386
    By:
    • Kapidzic, A.;
    • Korfage, I. J.;
    • van Dam, L.;
    • van Roon, A. H. C.;
    • Reijerink, J. CIY;
    • Zauber, A. G.;
    • van Ballegooijen, M.;
    • Kuipers, E. J.;
    • van Leerdam, M. E.
    Publication type:
    Article
    18
    19
    20
    21
    22

    Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR.

    Published in:
    British Journal of Cancer, 2012, v. 107, n. 8, p. 1392, doi. 10.1038/bjc.2012.412
    By:
    • Dyrskjøt, L.;
    • Reinert, T.;
    • Novoradovsky, A.;
    • Zuiverloon, T. C. M.;
    • Beukers, W.;
    • Zwarthoff, E.;
    • Malats, N.;
    • Real, F. X.;
    • Segersten, U.;
    • Malmström, P.-U.;
    • Knowles, M.;
    • Hurst, C.;
    • Sorge, J.;
    • Borre, M.;
    • Ørntoft, T. F.
    Publication type:
    Article
    23
    24

    Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.

    Published in:
    British Journal of Cancer, 2012, v. 107, n. 8, p. 1257, doi. 10.1038/bjc.2012.370
    By:
    • Earl, H. M.;
    • Hiller, L.;
    • Dunn, J. A.;
    • Vallier, A.-L.;
    • Bowden, S. J.;
    • Jordan, S. D.;
    • Blows, F.;
    • Munro, A.;
    • Bathers, S.;
    • Grieve, R.;
    • Spooner, D. A.;
    • Agrawal, R.;
    • Fernando, I.;
    • Brunt, A. M.;
    • O'Reilly, S. M.;
    • Crawford, S. M.;
    • Rea, D. W.;
    • Simmonds, P.;
    • Mansi, J. L.;
    • Stanley, A.
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32

    Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.

    Published in:
    British Journal of Cancer, 2012, v. 107, n. 8, p. 1409, doi. 10.1038/bjc.2012.391
    By:
    • Schramm, A.;
    • Schowe, B.;
    • Fielitz, K.;
    • Heilmann, M.;
    • Martin, M.;
    • Marschall, T.;
    • Köster, J.;
    • Vandesompele, J.;
    • Vermeulen, J.;
    • de Preter, K.;
    • Koster, J.;
    • Versteeg, R.;
    • Noguera, R.;
    • Speleman, F.;
    • Rahmann, S.;
    • Eggert, A.;
    • Morik, K.;
    • Schulte, J. H.
    Publication type:
    Article
    33
    34
    35
    36
    37